{
    "nct_id": "NCT06780137",
    "official_title": "A Phase 1b/2 Open-Label Clinical Study to Evaluate the Safety and Efficacy of MK-6070 and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer",
    "inclusion_criteria": "* Has histologically or cytologically confirmed SCLC that is extensive stage (defined as Stage IV (T any, N any, M1a/b/c) following at least 1 prior line of systemic therapy that included platinum-based chemotherapy\n* Must be able to provide archival tissue sample or fresh biopsy tissue sample\n* Human immunodeficiency virus (HIV) infected participants must have well controlled HIV on antiretroviral therapy (ART)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedure\n* History of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids or has current pneumonitis/ILD, and or suspected ILD/pneumonitis\n* Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses\n* History of clinically significant intracranial bleeding or spinal cord bleeding\n* Active neurologic paraneoplastic syndrome\n* Active or history of immune deficiency with the exception of HIV-infected participants with well controlled HIV on ART\n* History within 6 months before the first dose of study intervention of coronary/peripheral artery bypass graft and/or any coronary/peripheral angioplasty or clinically significant cardiovascular disease such as myocardial infarction, symptomatic congestive heart failure (CHF) (New York Heart Association > class II), and/or uncontrolled cardiac arrhythmia\n* Has other uncontrolled or significant protocol-specified cardiovascular disease\n* History of arterial thrombosis (eg, stroke or transient ischemic attack) within 6 months before the first dose of study intervention\n* Chronic liver disease, including liver cirrhosis of Child-Pugh class B or C\n* Active clinically significant infection requiring systemic therapy\n* History of allogeneic tissue/solid organ transplant\n* History of leptomeningeal disease\n* Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids\n* Ongoing treatment with immunosuppressive medications, with protocol-specified exceptions\n* Known additional malignancy that is progressing or has required active treatment within the past 3 years\n* Untreated or symptomatic brain metastases\n* Active viral hepatitis, defined as hepatitis A (hepatitis A virus immunoglobulin M [IgM] positive in the setting of associated signs/symptoms), hepatitis B (hepatitis B virus surface antigen [HbsAg] positive and/or detectable hepatitis B virus (HBV) deoxyribonucleic acid [DNA]), or hepatitis C (hepatitis C virus [HCV] antibody positive and detectable HCV ribonucleic acid). Participants with HBV with undetectable viral load after treatment are eligible. Participants with HCV with undetectable virus after treatment are eligible.\n* Part 1 only: Radiation therapy to the lung >30 Gy within 6 months before the start of study intervention\n* Part 1 only: Abdominal radiation within 4 weeks before start of study intervention\n* Part 1 only: Other anticancer therapy, including cytotoxic agents, targeted agents, immunotherapies, antibody, retinoid, transplant, or anticancer hormonal treatment (except luteinizing hormone-releasing hormone [LHRH]) within 2 weeks before start of study intervention\n* Part 1 only: Antibody-based cancer therapy within 3 weeks before start of study intervention\n* Part 1 only: Chloroquine/hydroxychloroquine within 2 weeks before start of study intervention\n* Part 1 only: Clinically significant corneal disease",
    "miscellaneous_criteria": ""
}